Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 2:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 1,397 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Genentech, Inc. Clear all
Completed Phase 2Phase 3 Interventional Results available

Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis

NCT00104299
View directory record Official record
Conditions
Vasculitis, Wegener's Granulomatosis, Microscopic Polyangiitis
Interventions
Rituximab plus cyclophosphamide placebo (rituximab group), Cyclophosphamide plus rituximab placebo (control group), Azathioprine, Methylprednisolone (or other glucocorticoid), Prednisone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
15 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
7
States / cities
Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2017 · Synced Oct 30, 2026, 2:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Divarasib in Healthy Participants

NCT06835465
View directory record Official record
Conditions
Healthy Participants
Interventions
Divarasib, Rifampin
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 30, 2026, 2:10 PM EDT
Terminated Phase 3 Interventional

Rituximab Maintenance After Autologous Transplantation

NCT01103388
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
Rituximab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 30, 2026, 2:10 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Transformative Research in Diabetic Nephropathy 2.0

NCT07444203
View directory record Official record
Conditions
Diabetic Nephropathies, Kidney Diseases, Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
Interventions
Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Renin-angiotensin-aldosterone system blockade, Glucagon-like peptide-1 receptor agonists (GLP 1 RA), Mineralocorticoid Receptor Antagonists(MRAs)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 30, 2026, 2:10 PM EDT
Completed Phase 2 Interventional

Metronomic Low-Dose Cyclophosphamide and Methotrexate With or Without Bevacizumab in Treating Women With Metastatic Breast Cancer

NCT00083031
View directory record Official record
Conditions
Breast Cancer
Interventions
bevacizumab, cyclophosphamide, methotrexate
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
4
States / cities
Boston, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Oct 30, 2026, 2:10 PM EDT
Completed No phase listed Observational

Pharmacokinetics of Oseltamivir in Newborns and Infants

NCT01388439
View directory record Official record
Conditions
Prematurity of Fetus
Interventions
Oseltamivir
Drug
Lead sponsor
St. Louis Children's Hospital
Other
Eligibility
Up to 6 Months
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 6, 2011 · Synced Oct 30, 2026, 2:10 PM EDT
Completed Phase 2 Interventional Results available

Cardiac Safety Study in Patients With HER2 + Breast Cancer

NCT01904903
View directory record Official record
Conditions
HER2 Positive Breast Cancer, Left Ventricular Function Systolic Dysfunction
Interventions
Trastuzumab, Pertuzumab, Ado Trastuzumab Emtansine
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 30, 2026, 2:10 PM EDT
Terminated Phase 2 Interventional Results available

Effect of Anti-IgE in Non-Allergic Asthma

NCT00162773
View directory record Official record
Conditions
Asthma
Interventions
omalizumab, Placebo
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2017 · Synced Oct 30, 2026, 2:10 PM EDT
Recruiting Phase 1Phase 2 Interventional

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

NCT05000294
View directory record Official record
Conditions
Bile Duct Cancer, Gall Bladder Cancer, Breast Cancer, Neuroendocrine Tumors, Ovarian Cancer, Pancreatic Adenocarcinoma, Soft Tissue Sarcoma, Vulvar Cancer, Prostate Cancer
Interventions
Atezolizumab, Tivozanib
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 30, 2026, 2:10 PM EDT
Completed Phase 2 Interventional Results available

Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas

NCT00597402
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma, Brain Tumor
Interventions
Avastin, Temozolomide, Radiation Therapy (XRT), Irinotecan
Drug · Radiation
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Oct 30, 2026, 2:10 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer

NCT00411788
View directory record Official record
Conditions
Breast Cancer
Interventions
Rapamycin, Trastuzumab
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Bridgeport, Connecticut • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 21, 2016 · Synced Oct 30, 2026, 2:10 PM EDT
Completed Phase 2 Interventional Results available

Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis

NCT03483012
View directory record Official record
Conditions
Breast Cancer
Interventions
Atezolizumab, Stereotactic radiosurgery (SRS)
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 30, 2026, 2:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of the Mechanisms of Asthma

NCT00595153
View directory record Official record
Conditions
Asthma
Interventions
Pulmicort
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2014 · Synced Oct 30, 2026, 2:10 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer

NCT01855828
View directory record Official record
Conditions
Her2-Positive Breast Cancer
Interventions
Pertuzumab, Trastuzumab, Paclitaxel, 5-fluorouracil, Epirubicin, Cyclophosphamide
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 30, 2026, 2:10 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period

NCT06524375
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Venetoclax, cBTKi Monotherapy
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
20
States / cities
Springdale, Arkansas • Aurora, Colorado • Jacksonville, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 30, 2026, 2:10 PM EDT
Completed Phase 1 Interventional

A Study of the Safety and Pharmacokinetics of PRO283698 in Patients With Rheumatoid Arthritis

NCT00888745
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
placebo, PRO283698
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
9
States / cities
Anniston, Alabama • Orlando, Florida • Ormond Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2010 · Synced Oct 30, 2026, 2:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Resilience-Based Program for Support Partners of Persons With Multiple Sclerosis

NCT03555253
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Resilience-Based Program for Support Partners of PwMS
Behavioral
Lead sponsor
Healios Inc.
Industry
Eligibility
21 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Flemington, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 30, 2026, 2:10 PM EDT
Recruiting Phase 4 Interventional

A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy

NCT07609719
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
OCR SC
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
7
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fort Collins, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 30, 2026, 2:10 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Rituximab to Treat Fibrillary Glomerulonephritis

NCT02197767
View directory record Official record
Conditions
Fibrillary Glomerulonephritis
Interventions
rituximab
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 79 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 30, 2026, 2:10 PM EDT
Terminated Phase 2 Interventional Results available

Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection

NCT05060003
View directory record Official record
Conditions
Stage II Melanoma
Interventions
Atezolizumab, Tiragolumab, Signatera Assay
Drug · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 30, 2026, 2:10 PM EDT
Completed Phase 2 Interventional Results available

Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer

NCT00234494
View directory record Official record
Conditions
Bladder Cancer
Interventions
Cisplatin, Gemcitabine, Bevacizumab
Drug
Lead sponsor
Christopher Sweeney, MBBS
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
11
States / cities
Chicago, Illinois • Galesburg, Illinois • Evansville, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 30, 2026, 2:10 PM EDT
Terminated Phase 1Phase 2 Interventional

Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

NCT04550442
View directory record Official record
Conditions
Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome, Therapy-Related Myelodysplastic Syndrome
Interventions
Azacitidine, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 30, 2026, 2:10 PM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer

NCT00821886
View directory record Official record
Conditions
Breast Cancer
Interventions
Ixabepilone, Trastuzumab, Carboplatin
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
12
States / cities
Fort Myers, Florida • Augusta, Georgia • Terre Haute, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2014 · Synced Oct 30, 2026, 2:10 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluate Whether Combination Therapy With Methotrexate and Raptiva in Psoriasis Patients is Safe and Increases Efficacy

NCT00368654
View directory record Official record
Conditions
Psoriasis
Interventions
Methotrexate, Raptiva
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 30, 2026, 2:10 PM EDT